anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

172,561-172,620 of 319,975

filter-aware
18
The slide uses a standard clinical trial flow diagram (CONSORT-style).AstraZeneca | Investor Day Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Satisfaction1 hit
19
The slide presents clinical trial baseline data for three cohorts.AstraZeneca | Investor Day Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Satisfaction1 hit
20
Clinical trial data visualization (Kaplan-Meier plot).AstraZeneca | Investor Day Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Satisfaction1 hit
21
Includes a landmark analysis at 9 months for hazard ratios.AstraZeneca | Investor Day Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Satisfaction1 hit
22
Clinical trial data presentation showing PFS, HR, and TTP metrics.AstraZeneca | Investor Day Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Satisfaction1 hit
23
Clinical trial safety data comparing combination therapy vs monotherapy vs standard of care.AstraZeneca | Investor Day Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Satisfaction1 hit
24
The table displays both 'All grades' and 'Grade ≥3' adverse events for specific medical conditions.AstraZeneca | Investor Day Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Satisfaction1 hit
25
AstraZeneca | Investor Day Presentation Deck | 42 slidesAstraZeneca | Investor Day Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Satisfaction1 hit
26
The slide features a stylized silhouette of a person with an internal biological/molecular visualization.AstraZeneca | Investor Day Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
27
Uses a before-after framing to contrast the status quo (problem) with the new clinical solution.AstraZeneca | Investor Day Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · ActionLoop · Cost Of Inaction1 hit
28
The slide uses a three-column layout to contrast the unmet need, the treatment mechanism, and the clinical outcomes.AstraZeneca | Investor Day Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · ActionLoop · Before After1 hit
29
The slide features a stylized silhouette of a human figure with internal biological/molecular imagery.AstraZeneca | Investor Day Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
30
The chart uses a bar chart for existing presence and a stacked bar for GI cancer segments.AstraZeneca | Investor Day Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
31
The slide uses a split-layout to contrast established late-stage assets (Imfinzi, Enhertu) with early-stage pipeline candidates.AstraZeneca | Investor Day Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
32
The slide features a stylized silhouette of a person with biological/molecular imagery inside, suggesting a life sciences or medical context.AstraZeneca | Investor Day Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Action1 hit
33
AstraZeneca | Investor Day Presentation Deck | 42 slidesAstraZeneca | Investor Day Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations 1 hit
34
AstraZeneca | Investor Day Presentation Deck | 42 slidesAstraZeneca | Investor Day Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations 1 hit
35
AstraZeneca | Investor Day Presentation Deck | 42 slidesAstraZeneca | Investor Day Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations 1 hit
36
The chart displays hazard ratios with 95% confidence intervals for different demographic and clinical categories.AstraZeneca | Investor Day Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations 1 hit
37
The slide includes a technical explanation of the TAP score methodology using the Ventana PD-L1 (SP263) Assay.AstraZeneca | Investor Day Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations 1 hit
38
AstraZeneca | Investor Day Presentation Deck | 42 slidesAstraZeneca | Investor Day Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations 1 hit
39
AstraZeneca | Investor Day Presentation Deck | 42 slidesAstraZeneca | Investor Day Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations 1 hit
40
The plot visualizes subgroup analysis for a clinical trial, indicating treatment efficacy across different patient demographics and clinical characteristics.AstraZeneca | Investor Day Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations 1 hit
41
AstraZeneca | Investor Day Presentation Deck | 42 slidesAstraZeneca | Investor Day Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations 1 hit
42
AstraZeneca | Investor Day Presentation Deck | 42 slidesAstraZeneca | Investor Day Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations 1 hit
01
Slide 1
ATAI | Investor Day Presentation Deck | 42 slidesATAI | Investor Day Presentation Deck | 42 slides · atai Life Sciences
Conference presentation Investor relations 1 hit
02
ATAI | Investor Day Presentation Deck | 42 slidesATAI | Investor Day Presentation Deck | 42 slides · atai Life Sciences
Conference presentation Investor relations 1 hit
03
ATAI | Investor Day Presentation Deck | 42 slidesATAI | Investor Day Presentation Deck | 42 slides · atai Life Sciences
Conference presentation Investor relations 1 hit
04
The slide uses a numbered list format to highlight key strategic pillars.ATAI | Investor Day Presentation Deck | 42 slides · atai Life Sciences
Conference presentation Investor relations 1 hit
05
Includes a highlighted row for RL-007 and a section for equity interests.ATAI | Investor Day Presentation Deck | 42 slides · atai Life Sciences
Conference presentation Investor relations 1 hit
06
ATAI | Investor Day Presentation Deck | 42 slidesATAI | Investor Day Presentation Deck | 42 slides · atai Life Sciences
Conference presentation Investor relations 1 hit
07
ATAI | Investor Day Presentation Deck | 42 slidesATAI | Investor Day Presentation Deck | 42 slides · atai Life Sciences
Conference presentation Investor relations 1 hit
08
ATAI | Investor Day Presentation Deck | 42 slidesATAI | Investor Day Presentation Deck | 42 slides · atai Life Sciences
Conference presentation Investor relations 1 hit
09
ATAI | Investor Day Presentation Deck | 42 slidesATAI | Investor Day Presentation Deck | 42 slides · atai Life Sciences
Conference presentation Investor relations Beat · Problem (Identify pain)1 hit
10
The slide uses icons to represent three key negative outcomes for the patient population.ATAI | Investor Day Presentation Deck | 42 slides · atai Life Sciences
Conference presentation Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
11
The slide uses a citation to support the data.ATAI | Investor Day Presentation Deck | 42 slides · atai Life Sciences
Conference presentation Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
12
Data source: Keefe et al, Schiz Res, 2011.ATAI | Investor Day Presentation Deck | 42 slides · atai Life Sciences
Conference presentation Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
13
The slide uses a causal chain diagram to link neurocognitive deficits to functional outcomes and a bar chart to show correlation strength.ATAI | Investor Day Presentation Deck | 42 slides · atai Life Sciences
Conference presentation Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
14
The chart uses a broken y-axis between 35 and 100 to accommodate the data distribution.ATAI | Investor Day Presentation Deck | 42 slides · atai Life Sciences
Conference presentation Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
15
The slide uses a comparative analysis between cancer and schizophrenia/CIAS to highlight resource allocation disparities.ATAI | Investor Day Presentation Deck | 42 slides · atai Life Sciences
Conference presentation Investor relations Beat · Agitate (Make it worse)1 hit
16
ATAI | Investor Day Presentation Deck | 42 slidesATAI | Investor Day Presentation Deck | 42 slides · atai Life Sciences
Conference presentation Investor relations Beat · Agitate (Make it worse)1 hit
17
The slide contrasts specific receptor-targeted programs with a more complex multi-receptor approach.ATAI | Investor Day Presentation Deck | 42 slides · atai Life Sciences
Conference presentation Investor relations 1 hit
18
The chart displays statistical significance markers (*) for specific time points and treatment groups.ATAI | Investor Day Presentation Deck | 42 slides · atai Life Sciences
Conference presentation Investor relations 1 hit
19
ATAI | Investor Day Presentation Deck | 42 slidesATAI | Investor Day Presentation Deck | 42 slides · atai Life Sciences
Conference presentation Investor relations 1 hit
20
ATAI | Investor Day Presentation Deck | 42 slidesATAI | Investor Day Presentation Deck | 42 slides · atai Life Sciences
Conference presentation Investor relations 1 hit
21
ATAI | Investor Day Presentation Deck | 42 slidesATAI | Investor Day Presentation Deck | 42 slides · atai Life Sciences
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Aha Moment1 hit
22
ATAI | Investor Day Presentation Deck | 42 slidesATAI | Investor Day Presentation Deck | 42 slides · atai Life Sciences
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Aha Moment1 hit
23
The slide uses a process flow to map research/clinical stages to specific de-risking milestones.ATAI | Investor Day Presentation Deck | 42 slides · atai Life Sciences
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
24
ATAI | Investor Day Presentation Deck | 42 slidesATAI | Investor Day Presentation Deck | 42 slides · atai Life Sciences
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
25
The slide includes a time-series line chart showing fEPSP slope over time and a bar chart showing fEPSP amplitude changes across different treatment conditions.ATAI | Investor Day Presentation Deck | 42 slides · atai Life Sciences
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
26
ATAI | Investor Day Presentation Deck | 42 slidesATAI | Investor Day Presentation Deck | 42 slides · atai Life Sciences
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
27
ATAI | Investor Day Presentation Deck | 42 slidesATAI | Investor Day Presentation Deck | 42 slides · atai Life Sciences
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
28
The table maps study types (HV PK, Scopolamine, Peripheral Diabetic Neuropathy) against Phase 1/2 status and key clinical endpoints (Safety/PK, Target Engaged, Biphasic).ATAI | Investor Day Presentation Deck | 42 slides · atai Life Sciences
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
29
The slide uses red dashed boxes to highlight the 40mg dose performance in both single and 7-day TID dosing scenarios.ATAI | Investor Day Presentation Deck | 42 slides · atai Life Sciences
Conference presentation Investor relations 1 hit
30
Includes EEG brain mapping, cognitive test results (Continuity of Attention, Delayed Word Recall), and DPNP study data.ATAI | Investor Day Presentation Deck | 42 slides · atai Life Sciences
Conference presentation Investor relations 1 hit
31
ATAI | Investor Day Presentation Deck | 42 slidesATAI | Investor Day Presentation Deck | 42 slides · atai Life Sciences
Conference presentation Investor relations 1 hit
32
ATAI | Investor Day Presentation Deck | 42 slidesATAI | Investor Day Presentation Deck | 42 slides · atai Life Sciences
Conference presentation Investor relations 1 hit
33
The slide outlines a clinical trial design including screening, in-patient dosing, and follow-up phases.ATAI | Investor Day Presentation Deck | 42 slides · atai Life Sciences
Conference presentation Investor relations 1 hit
34
The table uses directional arrows to indicate the direction of change in qEEG endpoints across different cohorts and brain regions (F, C, T, P, O).ATAI | Investor Day Presentation Deck | 42 slides · atai Life Sciences
Conference presentation Investor relations 1 hit
35
The slide presents clinical trial data comparing ERP responses (MMN and P300b) across different dose levels of RL-007.ATAI | Investor Day Presentation Deck | 42 slides · atai Life Sciences
Conference presentation Investor relations 1 hit